Caliway Biopharmaceuticals Co., Ltd. Stock Price

TWSE:6919 Community·NT$192.3b Market Cap

0 Narratives written by author
0 Comments on narratives written by author
16 Fair Values set on narratives written by author

Create a narrative

6919 Share Price Performance

NT$0

-51.00 (-100.00%)

NT$0

-51.00 (-100.00%)

NT$0

Mon, 17 Nov 25

Share Pricen/a

6919 Community Narratives

There are no narratives available yet.

Create a narrative

There are no community narratives available.

Snowflake Analysis

High growth potential with excellent balance sheet.

2 Risks

2 Rewards

View Full Analysis

Caliway Biopharmaceuticals Co., Ltd. Key Details

Last Reported Earnings

Sep 30, 2025

Next Reporting Earnings

n/a

: -0.31
: 69.62%
: -1,395.39%
: 0%

View Full Analysis

About 6919

Founded: 2012
Employees: n/a
CEO: Yufang Ling
WebsiteView website: www.caliway.com.tw

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum’s disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.